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ABSTRACT
Agents which increase intracellular cyclic
adenosine monophosphate (cAMP) may have
an antagonistic effect on pro-inflammatory
molecule production so that inhibitors of the
cAMP degrading phosphodiesterases have been
identified as promising drugs in chronic
inflammatory disorders. Although many such
inhibitors have been developed, their
introduction in the clinic has been hampered
by their narrow therapeutic window with side
effects such as nausea and emesis occurring at
sub-therapeutic levels. The latest generation of
inhibitors selective for phosphodiesterase 4
(PDE4), such as apremilast and roflumilast,
seems to have an improved therapeutic index.
While roflumilast has been approved for the
treatment of exacerbated chronic obstructive
pulmonary disease (COPD), apremilast shows
promising activity in dermatological and
rheumatological conditions. Studies in
psoriasis and psoriatic arthritis have
demonstrated clinical activity of apremilast.
Efficacy in psoriasis is probably equivalent to
methotrexate but less than that of monoclonal
antibody inhibitors of tumour necrosis factor
(TNFi). Similarly, in psoriatic arthritis efficacy is
less than that of TNF inhibitors. PDE4 inhibitors
hold the promise to broaden the portfolio of
anti-inflammatory therapeutic approaches in a
range of chronic inflammatory diseases which
may include granulomatous skin diseases, some
subtypes of chronic eczema and probably
cutaneous lupus erythematosus. In this review,
the authors highlight the mode of action of
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PDE4 inhibitors on skin and joint inflammatory
responses and discuss their future role in
clinical practice. Current developments in the
field including the development of topical
applications and the development of PDE4
inhibitors which specifically target the
subform PDE4B will be discussed.
Keywords: Apremilast; Chronic inflammatory
disease; Dermatology; Phosphodiesterase
inhibition; Psoriasis; Psoriatic arthritis;
Treatment
INTRODUCTION
The clinical symptoms of chronic inflammatory
diseases are determined by a number of
different inflammatory mediators. In psoriasis,
for example, not only the well-recognized
tumour necrosis factor (TNF) is an important
effector molecule, but interleukin 17 (IL-17), IL-
22, interferon c (IFNc), IL-2, IL-36, CCL20, IL-8,
chemokine CXCL10, IL-23, IL-1, IL-18, IL-12,
vascular endothelial growth factor (VEGF),
substance P, IFNa, and many others contribute
to the inflammatory response both in the joint
and skin compartment. Conventional therapies
have a broad range of action and inhibit, e.g.
preferentially lymphocyte proliferation
[cyclosporin (CsA), methotrexate] and
lymphokine production (IFNc, IL-17, IL-22,
IL-2) or mainly target the hyperproliferation
and abnormal differentiation of keratinocytes
(dithranol, tar) or combine the latter with
cytokine modifying properties (retinoids,
vitamin D, glucocorticoids). Biologics currently
used in the clinic target one specific mediator
which supposedly plays a key role upstream in
the disease-specific cytokine network. An
approach which interferes with several
inflammatory mediators without the side
effects seen with conventional
immunosuppressants is of high interest.
Interfering with the intracellular levels of
cyclic adenosine monophosphate (cAMP) was




cAMP is a key intracellular second messenger
(Fig. 1) [1]. cAMP signalling is activated by a
variety of G protein-coupled receptor ligands.
The effects of cAMP are transduced by two
ubiquitously expressed intracellular cAMP
receptors, protein kinase A (PKA) and
exchange protein directly activated by cAMP
(EPAC). cAMP can also bind to cyclic
nucleotide-gated ion channels in certain
tissues. The latter cAMP activity plays a role in
the clinical symptoms of cholera. Cholera toxin
subunit B causes un-leashed cAMP production
and consequently chloride secretion through
the apical chloride channel into the lumen of
the small intestine leading to severe diarrhoea
and dehydration [2]. cAMP actions are highly
cell type- and context-dependent. cAMP and its
downstream signalling are involved in a
plethora and large diversity of cellular
responses. A key feature of the cAMP/cAMP-
dependent PKA transduction system is the
compartmentalization of its signalling
molecules and effectors. This means that local
pools of cAMP expression/PKA activation are
generated in distinct subcellular compartments.
This allows for precisely regulated activity
essential for response specificity. cAMP
activates and enables PKA to phosphorylate
substrate proteins. PKA activates cAMP
response element binding protein (CREB)
which is a cAMP-responsive element possessed
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by several immune-related genes including IL-2,
IL-6, IL-10, and TNFa (for review: [3]). cAMP can
directly or indirectly (via phosphorylated CREB)
inhibit nuclear factor kappa B (NF-jB) pathway
activation events. Low intracellular cAMP may
thus lead to the preferential expression of
proinflammatory mediators. The above
mentioned EPAC can activate the Ras-related
small guanosine triphosphate (GTP) Rap1 and
this activation can lead to biological responses
including induction of phagocytosis, and
vasorelaxation [4–7].
Intracellular concentration of cAMP is
determined by the activity of adenylyl cyclases
[synthesises cAMP from adenosine triphosphate
(ATP)] on the one hand and phosphodiesterases
(PDE) on the other. PDEs are also expressed in
distinct cellular compartments and functionally
coupled to individual receptors—thus providing
a way to control sub-compartment cAMP levels
in a stimulus-specific manner.
The Role of cAMP in Inflammatory
Immune Responses
Substances which increase cAMP in monocytes/
macrophages are among the most potent
inhibitors of IL-12 family members including
IL-12/IL-23 p40. This has been shown for
cholera toxin [8–14], histamine [15–19],
prostaglandin E2 (PGE2) [20] and other
mediators. Another milestone in the
investigation of cAMP’s role in immune
responses was the finding by Bopp et al. [21]
that one of the effector mechanisms underlying
T regulatory (Treg) function is the contact-
Fig. 1 Cellular pathways involving cyclic adenosine mono-
phosphate (cAMP). Reproduced from Schafer [1], with
permission from Elsevier. AC adenylyl cyclase, ATF-1
activating transcription factor, ATP adenosine triphosphate,
CBP CREB-binding protein, CREB cAMP response element
binding protein, CREM cAMP response element modulator,
EPACs exchange protein directly activated by cAMP, Gas G
protein alpha subunit, GPCR G protein coupled receptors,
IFN interferon, IKKb inhibitor of nuclear factor kappa B
kinase subunit beta, IL interleukin, IRAK interleukin-1
receptor-associated kinase, IjB inhibitor of NF-jB, NF-jB
nuclear factor kappa B, PDE4 phosphodiesterase 4, PG
prostaglandin, PKA protein kinase A, TLR4 toll-like recep-
tor 4, TNF tumour necrosis factor, TRAF6 TNF receptor-
associated factor
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dependent transfer of cAMP via gap-junctions
into target cells. Repression of cAMP greatly
reduces the suppressive activity of human Treg
[22]. cAMP facilitates the functional activity of a
transcriptional inhibitor called ICER (inducible
cAMP early repressor) and this mechanism
seems to be involved in the suppression of the
key T cell growth factor IL-2 [23] and other
cytokines [24]. In addition, immunosuppressive
and anti-inflammatory actions of cAMP have
been attributed in part to the ability of cAMP-
induced signals to interfere with the function of
NF-jB [25]. NF-jB activation is one of the
master signalling pathways involved in
inflammatory responses and a key target for
anti-inflammatory drug design. Important
cytokines downstream of NF-jB include TNFa,
CCL20, IL-8; IL-1 family members (IL-36, IL-18,
IL-1) and (in combination with a priming
signal) also IL-12 family members (IL-12, IL-
23, IL-27) and many more.
The cAMP system is also involved in a variety
of epithelial functions and plays a role in
maintenance of the skin barrier. In the
keratinocyte cell line HaCat largely suppressed
chemokine production (CXCL10, CCL17, and
CCL22) has been described [26, 27] in the
context of increased cAMP levels.
PHOSPHODIESTERASE 4 (PDE4)
There are several PDE families, all isoforms of
which are concerned with the intracellular
degradation of the phosphodiesterase bonds of
cAMP and cyclic guanosine monophosphate
(cGMP). PDE4, -7, and -8 degrade cAMP
specifically. PDE4 is encoded by four separate
genes (PDE4 A–D) and each PDE4 controls non-
redundant cellular functions. Inhibition of
PDE4 activity leads to elevated levels of
intracellular cAMP.
PDE4s are the predominant cAMP degrading
isoenzymes in most immune cells including
lymphocyte subsets, granulocytes and cells of
the monocyte/macrophage lineage [28]. They
are also expressed in epithelial cells, vascular
endothelium, chondrocytes and smooth muscle
cells. The role of PDE4 in immune cells has
recently been reviewed by Jin et al. [29], and for
respiratory diseases by Page and Spina [30]. In
immune cells, the isoforms PDE4A, B and D (but
not C) are highly expressed as well as PDE3 and
7 [30]. It is noteworthy, however, that the
activity of macrophages may not be
significantly inhibited by PDE4 selective
inhibitors [31]. The benefit of a combined
effect of PDE7 or PDE3 with PDE4 selective
inhibitors on macrophage and T cell function
has been described [32, 33].
The expression levels of these PDE
isoenzymes are regulated by a variety of
stimuli. For example, prostaglandin E2 induces
PDE3 and 4 activity and PDE3B, 4A4, 4A1, 4D2
and 4D3 expression [34]. T cell receptor
stimulation increases the differential
expression of PDE4 subtypes in cluster of
differentiation 4 (CD4?T) cells [35], and toll-
like receptor 4 (TLR4) stimulation acts on
PDE4B2 expression in human monocytes [36].
PDE INHIBITORS
Non-Selective PDE Inhibitors
Pentoxifylline is a competitive non-selective
PDE inhibitor (used in the treatment of
peripheral vascular disease) which raises
intracellular cAMP levels to inhibit TNF and
reduce inflammation. Pentoxifylline is also an
adenosine 2 receptor antagonist. It reduces
blood viscosity and platelet aggregation.
Although suggested by some authors,
4 Dermatol Ther (Heidelb) (2013) 3:1–15
123
pentoxifylline is not effective on the activity of
psoriasis [37]. Some beneficial effect has been
reported in canine atopic dermatitis [38] and
human lung sarcoidosis [39].
Theophylline inhibits to some extent PDE1-5
(least effective against PDE4; [40]), is a potent
adenosine receptor antagonist and an activator
of histone deacetylase 2 (HDAC2) such that it
might exert beneficial effects on (allergic) lung
inflammation [41].
Selective PDE4 Inhibitors
By increasing cAMP levels, PDE4 inhibitors
show anti-inflammatory effects in almost all
inflammatory cells. Numerous selective PDE4
inhibitors have been patented in the past two
decades and some of them have been evaluated
in clinical trials for several inflammatory
conditions including asthma, chronic
obstructive pulmonary disease (COPD), atopic
dermatitis (AD), and rheumatoid arthritis (RA).
Inhibitors of different structural classes have
been developed but discontinued for most of
these compounds because of narrow
therapeutic windows. Doses needed for
efficacy could not be reached due to dose-
limiting adverse events with nausea, diarrhoea,
abdominal pain, vomiting, and dyspepsia being
the most common. Adverse events of PDE4
inhibitors are evoked through the inhibition of
PDE4 in non-target tissue at doses similar to
those needed for therapeutic efficacy. It is
believed that the inhibition of enzymes
encoded by PDE4D in non-target tissues
promotes emesis [42]. Thus, the development
of PDE4 inhibitors with improved therapeutic
indices has been a major focus of
pharmaceutical research. Development of
PDE4 inhibitors with different delivery routes
such as topical application [43] and inhalation
(outlined in Page and Spina [30]) are also under
development for the treatment of airway
inflammation and dermatitis. AN2728 which
inhibits PDE4 has been administered topically
in phase 2 studies to patients with psoriasis or
AD [44, 45].
The first orally active PDE4 inhibitor
roflumilast [46] was approved in 2010 by the
European Medicines Agency for severe COPD
associated with chronic bronchitis in adult
patients. In March 2011 the U.S. Food and
Drug Administration (FDA) approved it for
reducing COPD exacerbations. PDE4 and its
inhibition have been studied extensively in the
treatment of COPD and asthma [46, 47].
Recent human clinical data on PDE4
inhibitors on skin diseases and in particular on
psoriasis are available for apremilast. Apremilast
is an orally available PDE4 inhibitor [48] which
does not show any marked selectivity among
the PDE4 isotypes. It seems to elicit less emetic
side effects while also having a wide therapeutic
window. The underlying mechanism for this
increased tolerability is not known. The effects
of apremilast—which are in line with findings
reported for increased intracellular cAMP
levels—on a range of pro-inflammatory
responses in a variety of cells have recently
been comprehensively summarized [1].
Unsurprisingly, all PDE4 inhibitors have the
potential to reduce the expression of TNFa
which is considered a key mediator in a
number of inflammatory diseases. Crilly et al.
[49] have demonstrated that specific PDE4
inhibitors dose-dependently down regulate the
release of TNFa and other cytokines including
CCL2, CCL3 (and to a lesser extent IL-1ß) from
primary RA synovial digest suspensions.
McCann et al. [50] have demonstrated TNFa
inhibition in human rheumatoid synovial
membrane cultures for apremilast. It is of
interest that some PDE4 subtypes such as
PDE4B seem to be more concerned with the
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inhibition of TNF production in murine
monocyte/macrophages [51, 52]. Apremilast
has inhibitory activity on TNFa release by
ultraviolet B (UVB) activated (50 mJ/cm2)
keratinocytes [53].
PDE4 Inhibitors in Dermatologic Diseases
Data suggest a promising therapeutic effect for
selective PDE4 inhibitors on inflammatory skin
diseases [54]. Of note, a PDE7A inhibitor was
also successful in suppressing dermatitis and
TNF expression in mice studies [55]. In
a humanised [severe combined
immunodeficiency (SCID) mice, grafted
human psoriasis skin triggered with psoriatic
natural killer (NK) cells] psoriasis model oral
apremilast led to significant reduction
in epidermal lesion thickness [54]. The
psoriasiform histology was clearly reduced
with regard to parakeratosis, hyperkeratosis,
lymphocytic and neutrophilic infiltration.
Clinical studies for psoriasis are summarized
below.
One study points to a potentially beneficial
effect of apremilast in cutaneous sarcoidosis
[56] and it will be interesting to further
explore the activity of PDE4 inhibitors in
granulomatous skin diseases including
Melkerson Rosenthal syndrome for which the
therapeutic options are limited at present.
Although PDE4 selective inhibitors inhibit IL-
12 and TNF a mixed PDE4/3/7 preparation
may have improved activity on macrophages
which are key cells in granulomatous diseases.
PDE4 inhibitors may be of benefit in lupus
erythematosus (LE) [57]. For example, a
recently published open-label, single arm
pilot study with apremilast showed
favourable results of a 20 mg twice daily (bd)
dose regime in cutaneous discoid lupus
erythematosus [58]. Apremilast was well
tolerated in these patients.
For skin diseases, the availability of topical
preparations (as mentioned above) is of high
interest and ongoing trials are exploiting the
potency of topical PDE4 inhibition [44, 45]. The
anti-fibrotic effect makes PDEs potential drugs
for the treatment of scleroderma. However,
PDE5 inhibitors seem more promising in this
disease as well as in the treatment of secondary
Raynaud’s phenomenon (improvement of
endothelial dysfunction and prevention of
vascular remodelling) [59].
PDE4 inhibitors including apremilast have
beneficial effects in animal models of
dermatitis, in particular allergic contact
dermatitis (ACD, for review [60]). The
elicitation phase of ACD follows a Th1 like
dominated response pattern where contact
allergens impact on TLR activation, reactive
oxygen species (ROS) and NLRP3
inflammasome activation which are key
mechanisms in the induction phase of ACD
[61–63]. As mentioned above, inhibition of ROS
production may be better achieved in vitro by
combined PDE inhibitors (PDE4 and 3 or 7).
Two clinical studies on AD have recently
been published [64, 65]. Samrao et al. [64] used
apremilast at 2 doses (20 and 30 mg bd, for
3 months, 6 months) in an open-label study
with 16 adult AD patients. They found a
reduced Eczema Area and Severity Index (EASI)
and Dermatology Life Quality Index (DLQI) for
the 30 mg group at 3 months and a reduction in
baseline pruritus and DLQI in the 20 mg group
after 3 and 6 months time. Volf et al. [65]
performed a phase 2, open-label study with
apremilast in patients suffering from severe
ACD or AD. A dose of 20 mg bd was given for
3 months in 10 patients with AD and/or ACD.
Apremilast was well tolerated but was only
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minimally effective in this small study with a
heterogeneous study population.
From what is known on PDE4 action on
lymphocytes, macrophages/dendritic cells
subtypes, eosinophils and mast cells (for review,
[29]) the overall net effect of PDE4 inhibitors
seems more prominent for IFNc or IL-17
dominated immune responses than IL-4/5/13
one [66]. Interestingly, a better effect on IFNc
dominated inflammation has been described for
Treg in vivo studies [67]. Indeed, the effect of IL-4
on B cell function can even be accentuated. This
leads to the notion that PDE4 inhibitors may be
more potent in the treatment of IL-12/IL-23, thus
IFNc/IL-17 dominated responses than Th2 ones.
Based on this consideration, apremilast may be
effective in the effector phase of ACD, psoriasis
and in the very chronic phases of AD in which the
initial Th2 pattern has switched to a more Th1
dominated phenotype in the skin compartment
[68]. In chronic AD the topical application may be
the desirable way of application as the Th2
dominated response pattern in the blood of
atopic individuals remains unaltered.
CLINICAL STUDIES IN PSORIASIS
A small (19 patients) single arm, open-label pilot
study was performed in subjects with moderate
to severe plaque psoriasis. Patients were treated
for 29 days with 20 mg od of apremilast [69].
CD11c cells, T cells and epidermal thickness
were reduced. Immunohistologic analysis of
lesional-skin biopsies showed reduction in
epidermal thickness and reduced infiltration of
T cells and CD11c cells in responder patients.
Psoriasis Area and Severity Index (PASI) was
improved in 14 out of 19 patients.
The efficacy of apremilast in psoriasis has
been assessed in a phase 2b study using doses of
10, 20, and 30 mg bd with a placebo comparator
[70]. In this study, 352 patients were enrolled
with active psoriasis of moderate severity [PASI
of more than or equal to 12 or a body surface
area affected by psoriasis of more than or equal
to 10%, although mean baseline scores for PASI
and body surface area (BSA) were 18.5% and
22%, respectively] who were candidates for
phototherapy or systemic therapy. The
primary target was the proportion of subjects
achieving 75% improvement in PASI (PASI75)
at 16 weeks (the placebo controlled phase). At
16 weeks patients on placebo could be re-
randomised to active treatment but the dose
was still concealed to both patient and
physician. Further outcomes were assessed at
24 weeks. At 16 weeks PASI75 was achieved by
6% of patients on placebo, 11% of those on
10 mg bd, 29% of those on 20 mg bd, and 41%
of those on 30 mg bd. The results for apremilast
20 mg bd and 30 mg bd were significantly
different from placebo. The median number of
days to achieve PASI75 was 57 for placebo and
70, 83, and 44 for 10, 20 and 30 mg bd,
respectively. At week 16 13% of patients
on placebo were ‘clear or almost clear’ on
the physicians global assessment; the
corresponding figures for apremilast were 10%,
24%, and 33% for 10, 20, and 30 mg bd,
respectively. Adverse events were largely mild
to moderate: upper respiratory tract infections,
gastrointestinal symptoms (diarrhoea and
nausea), and headache were the most frequent
of these in the active treatment groups. No
opportunistic infections were seen [70].
CLINICAL STUDIES IN PSORIATIC
ARTHRITIS
In psoriatic arthritis there is only one published
study of the efficacy of apremilast—a phase 2
randomized placebo controlled study [71]. The
Dermatol Ther (Heidelb) (2013) 3:1–15 7
123
results of the phase 3 PALACE-I study were
presented at the American College of
Rheumatology (ACR) meeting in Washington
DC in November 2012 [72].
The phase II study enrolled 204 patients with
active psoriatic arthritis, defined by more than
or equal to 3 tender and 3 swollen joints. Only
co-prescription with a stable dose of
methotrexate or oral glucocorticoids was
allowed: all other disease modifying drugs had
to be discontinued before enrolment. The usual
restrictions on major co-morbid conditions
applied. Patients were randomized equally to
placebo, apremilast 20 mg bd or apremilast
40 mg once daily (od), stratified by baseline
methotrexate use. After 12 weeks of treatment
patients could stop treatment or enter a further
12 week extension phase, the latter option
occurring as an amendment to the original
protocol design, and re-randomisation of
placebo to one of the active treatment groups.
The primary efficacy endpoint was the
proportion of patients achieving a modified
(by joint count) ACR 20% improvement at
12 weeks (ACR20). The primary endpoint was
achieved by 43.5% of patients in the apremilast
20 mg bd group, 35.8% of patients in the 40 mg
od group, and 11.8% of patients on placebo, the
differences between active drug and placebo
being highly significant (see Table 1) [71, 72]. In
the extension phase, where patients who had
initially taken placebo were transferred to an
active drug, a similar improvement was seen in
the people who transferred, and the initial
improvements in the active treatment groups
were maintained. Stratified for methotrexate
use there was no difference in primary outcome
between the two groups, although more people
on combination had gastro-intestinal side
effects. No assessments of skin, enthesitis,
dactylitis, or axial involvement were made in
this study. Overall safety data were good with
diarrhoea and headache being the major, albeit
no more than moderate, side effects. Abnormal
laboratory results, including liver enzyme
elevations, were infrequent.
The PALACE-I study has only been reported
in abstract form [72]. This study enrolled 504
patients with active psoriatic arthritis (more
than three tender and swollen joints) who were
randomized in an equal ratio to placebo,
apremilast 20 mg bd and apremilast 30 mg bd.
The patients were stratified by previous disease
modifying drug use and about three quarters
were TNF inhibitor naive. The primary outcome
measure was again the ACR20 at 16 weeks
which was achieved by 19.4%, 31.3%, and
41% of the placebo, 20 and 30 mg bd groups,
respectively. At 24 weeks the corresponding
figures for per protocol treatment (i.e. those
Table 1 American College of Rheumatology 20% improvement (ACR20) rates for apremilast in phase 2 and phase 3
studies
Phase 2 Phase 3 (PALACE-I)
12 weeks Switch to active drug 24 weeks 16 weeks 24 weeks
Placebo 11.8 D1 40.0 19.4 13.0
D2 45.0 – –
D1 43.5 – 42.5 31.3 36.0
D2 35.8 – 43.5 41.0 45.0
All figures are percentages D1 for phase 2 and phase 3 was 20 mg twice daily (bd) D2 for phase 2 was 40 mg once daily (od),
for phase 3 was 30 mg bd [71, 72]
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still taking placebo) were ACR20 of 13%, 36%,
and 45%. Patients on placebo had the chance to
re-randomise to active drug at 16 weeks and a
long-term extension for all patients is
underway. As expected, patients who had
previously taken biologics had less impressive
responses, the ACR20 rates for the 20 and
30 mg bd groups at 16 weeks being 31% and
28%, respectively. Those taking disease
modifying drugs (mostly methotrexate) had
rather blunted responses (ACR20 rates of 31%
and 35% for 20 and 30 mg bd, respectively).
Skin responses were also reported: in patients
with a skin surface area of greater than 3% at
baseline the PASI75 rates at week 24 were 5%,
18% and 21% for placebo, 20 mg bd and 30 mg
bd, respectively. Serious adverse events were
rare and, again, adverse events were mainly
gastrointestinal (diarrhoea and nausea) and
headache, but a small increase in upper
respiratory infections was also seen [72].
DISCUSSION
In summary PDE4 inhibitors are orally active
agents with a good short-term safety that have
therapeutic possibilities in a variety of
inflammatory disorders. In psoriasis,
apremilast has moderate efficacy in psoriasis
and the associated psoriatic arthritis. What is
the likely use of this drug in clinical practice? It
is worth considering the current treatment
algorithms in use in this disease. Psoriasis and
psoriatic arthritis will be considered separately
and then as a combined approach.
From the data available so far PDE4 inhibitors
such as apremilast may be a valuable addition to
the psoriasis treatment portfolio. Their place
may be similar to fumaric acid and methotrexate
as systemic monotherapy in mild to moderate
psoriasis not sufficiently responsive to topical
glucocorticoids and vitamin D derivatives.
Apremilast shares functional properties with
fumaric acid with respect to suppression of
IL-12, IL-23, and TNF. Although drugs such as
apremilast seem to have a favourable side effect
profile, both direct comparison with other drugs
and long-term studies are needed to complete
the picture. Apremilast may also have an
advantage in women of child-bearing potential
in whom acitretin (and to a certain extent
methotrexate) is contra-indicated. It might also
be worth noting that PDE4 inhibitors could have
a beneficial effect on depressive disorders, a
common finding in patients with moderate to
severe psoriasis and psoriatic arthritis. PDE4
inhibitors appear less effective than TNFi in
psoriasis and they are also probably less effective
than CsA. However, combination therapy with
other immunomodulators may be an attractive
proposition both to reduce the dose of the other
immunomodulator and to reduce the side
effects of PDE4 inhibition. Drugs such as
apremilast may also be used as maintenance
therapy once remission has been induced by
another drug and it may help prevent relapses
often seen after withdrawal of, for example, CsA.
There are as yet no data on the safety profile of
PDE inhibitors with UV therapy but it would be
assumed that their safety profile would be
favourable when compared to drugs such as
methotrexate and CsA. In conclusion, from a
purely cutaneous perspective PDE4 inhibition is
probably similar to treatment with fumaric acid
and methotrexate, and probably less effective
than cyclosporin and TNF inhibitors.
Combination therapy may be the way forward
and novel applications such as the topical route
need exploration.
Psoriatic arthritis is a heterogeneous disease
with diverse clinical manifestations. From a
rheumatic point of view it is appropriate to
consider the condition as peripheral and axial
Dermatol Ther (Heidelb) (2013) 3:1–15 9
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arthritis [73]. Peripheral arthritis can be
considered as either oligoarticular (less than 4
joints) or polyarticular, although it should be
accepted that this division is somewhat
arbitrary. There is little other data to support the
split and, by use of sophisticated imaging
techniques, many cases of oligoarthritis are
found to be polyarticular. For this reason it is
difficult to design a single treatment algorithm to
cover all aspects of the disease. The situation is
complicated by the lack of evidence supporting
the use ofmany of the so called ‘disease modifying
drugs’ for use in psoriatic arthritis. Indeed, the
drug that is the mainstay of treatment of psoriatic
arthritis and the one that most rheumatologists
first turn at disease onset, methotrexate, has little
support from randomized controlled trials [74].
Further, methotrexate has no efficacy on the axial
disease [75]. Nevertheless, there is sufficient
evidence from both observational studies [76],
uncontrolled trials [77] and physicians own
experience for methotrexate to maintain a
pivotal role in the treatment of peripheral
psoriatic arthritis. Methotrexate is not without
problems: patients often complain of nausea, hair
thinning, and both physicians and patients worry
about hepatotoxicity, particularly in the
overweight patients and those who consume
moderate amounts of alcohol. If methotrexate
fails many physicians will be looking to use TNFi,
particularly, if there are adverse prognostic
factors. However, many European countries
advise the use of a second agent, such as
sulfasalazine or leflunomide, before moving
onto biologics.
Given this scenario how will apremilast fit
into such an algorithm? Although no head to
head trials have been conducted, from an
efficacy point of view it is likely that apremilast
is less effective than TNFi in the treatment of
both axial and peripheral arthritis. From the
point of view of peripheral arthritis an ACR20
rate of 41% at 12 weeks does not compare well
with TNFi (59% for etanercept, and 58% for
adalimumab, for example [78, 79]) although the
data currently available suggest that more
patients will achieve ACR20 with continued
exposure to apremilast. It is difficult to compare
the ACR rates with methotrexate although the
RESPOND [77] study, which was effectively open
label, found an ACR20 rate of 67% at 16 weeks.
The Methotrexate In Psoriatic Arthritis (MIPA)
study, in which doses of methotrexate were
modest, absolute rates of achieving ACR20 were
34% and 21% for methotrexate and placebo,
respectively, a difference that was not
statistically significant. Taken together these
two studies probably overestimate (RESPOND)
and underestimate (MIPA) the effect of
methotrexate on psoriatic arthritis.
Apremilast also has efficacy in the cutaneous
component of the disease, and, unlike
methotrexate, may have efficacy in the axial
component, present in about 40% of cases of
psoriatic arthritis. It is also worth noting that
there were no safety concerns of hepatotoxicity in
the short-term studies with apremilast so this
might confer advantages over methotrexate if a
physician was considering treatment in a patient
with risk factors for liver disease. However, it is
difficult to see physicians making major changes
to their prescribing habits given the current lack
of clear cut evidence for superiority of apremilast
and the concerns about the initial gastrointestinal
tolerability issues. Long-term familiarity and
safety concerns will also play a part in
prescribing patterns. And finally, the cost at
which the drug is marketed will have a major
impact on its position in the prescribing
hierarchy, particularly in cash strapped
economies and countries with ‘guidance’
mechanisms in place. Will apremilast be
positioned after TNFi in psoriatic arthritis? This
seems unlikely although it is possible to envisage
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a scenario where a patient may have failed a TNFi,
for whatever reason, and be offered another oral
therapy for their disease, although it would have
to be made clear that improvement rates after
failure of a TNFi are only moderate. It is worth
remembering though that achieving an ACR20,
although the yardstick by which drugs have been
tested of late in psoriatic arthritis, is not a very
good result for a patient—ACR rates of 50 or 70 are
needed for the patient to feel there has been real
improvement in their condition and these rates
were disappointingly low for apremilast.
CONCLUSION
PDE4 inhibitors are a class of drugs which act
intracellularly to down regulate inflammatory
pathways and to promote innate anti-
inflammatory pathways. They have a
potentially wide range of therapeutic uses in
chronic inflammatory diseases. In particular,
apremilast has already proven effective in
psoriasis and the peripheral arthritis of
psoriatic arthritis. Efficacy in psoriasis is
probably equivalent to methotrexate but less
than TNFi. In psoriatic arthritis efficacy is
probably similar to methotrexate but less than
TNFi. Apremilast appears to have a good safety
profile and this, together with the oral dosing
are likely to be major factors in the decision to
use the drug. However, much will depend on
the cost and long-term tolerability and safety.
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